By Elaine Rigoli
Tampa, Fla., March 23 - Mimetogen Pharmaceuticals, Inc. has completed a series A equity financing led by Boston-based Vimac Milestone Medica Fund with MSBi Capital returning as a co-investor.
The company has also completed negotiations with McGill University in Montreal for the exclusive worldwide rights to develop and commercialize novel technologies and therapeutics in the areas of cancer and glaucoma, according to a company news release.
Mimetogen's lead products are being developed to treat diseases for cancer and glaucoma.
Montreal, Quebec-based Mimetogen develops peptidomimetics as novel approaches to indications with high unmet medical needs.
| Issuer: | Mimetogen Pharmaceuticals, Inc.
|
| Issue: | Series A financing
|
| Investors: | Vimac Milestone Medica Fund, MSBi Capital
|
| Announcement date: | March 23
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
